LadRx Corporation
US ˙ OTCPK

Introduction

This page provides a comprehensive analysis of the known insider trading history of Steven A Kriegsman. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Steven A Kriegsman has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:CYTR / LadRx Corp Chief Executive Officer, Director 0
US:GALE / Galena Biopharma, Inc. Director 100,000
US:OTRKQ / Ontrak, Inc. Director 200,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Steven A Kriegsman. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases LADX / LadRx Corporation - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in LADX / LadRx Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2012-02-23 CYTR KRIEGSMAN STEVEN A 105,517 0.3265 17,586 1.9590 34,451 134 5.43 61,041 177.18
2012-02-22 CYTR KRIEGSMAN STEVEN A 53,159 0.3093 8,860 1.8558 16,442

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LADX / LadRx Corporation Insider Trades
Insider Sales LADX / LadRx Corporation - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in LADX / LadRx Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

LADX / LadRx Corporation Insider Trades
Insider Purchases OTRKQ / Ontrak, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in LADX / LadRx Corporation. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OTRKQ / Ontrak, Inc. Insider Trades
Insider Sales OTRKQ / Ontrak, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in LADX / LadRx Corporation. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

OTRKQ / Ontrak, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Steven A Kriegsman as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2020-08-13 2020-08-07 4 CYTR CYTRX CORP
Stock Option (right to buy)
M - Exercise -3,000,000 0 -100.00
2020-08-13 2020-08-07 4 CYTR CYTRX CORP
Common Stock, par value $0.001 per share
F - Taxes -1,164,179 3,668,038 -24.09 0.67 -780,000 2,457,585
2020-08-13 2020-08-07 4 CYTR CYTRX CORP
Common Stock, par value $0.001 per share
M - Exercise 3,000,000 4,832,217 163.74 0.26 780,000 1,256,376
2019-12-17 2019-12-13 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 3,000,000 3,000,000
2017-12-19 2017-12-15 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 208,334 208,334
2017-12-19 2017-12-15 4 CYTR CYTRX CORP
CytRx Common Stock
A - Award 387,597 387,597 1.75 678,295 678,295
2016-12-20 2016-12-15 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 1,250,000 1,250,000
2016-12-20 2016-12-15 4 CYTR CYTRX CORP
Common Stock
A - Award 2,325,581 2,325,581 0.43 1,000,000 1,000,000
2016-12-19 2016-12-15 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 1,250,000 1,250,000
2015-12-17 2015-12-15 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 1,000,000 1,000,000
2015-06-23 2015-06-19 4 GALE Galena Biopharma, Inc.
Stock Option (right to buy)
A - Award 100,000 100,000
2015-04-28 2015-02-17 4 CATS CATASYS, INC.
Stock Option to purchase Common Stock
A - Award 200,000 200,000
2014-12-16 2014-12-15 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 600,000 600,000
2014-04-09 2014-01-23 4 GALE Galena Biopharma, Inc.
Stock Option (right to buy)
M - Exercise -50,000 0 -100.00
2014-04-09 2014-01-23 4 GALE Galena Biopharma, Inc.
Stock Option (right to buy)
M - Exercise -100,000 0 -100.00
2014-04-09 2014-01-23 4 GALE Galena Biopharma, Inc.
Common Stock
S - Sale -150,000 5,000 -96.77 5.92 -888,540 29,618
2014-04-09 2014-01-23 4 GALE Galena Biopharma, Inc.
Common Stock
M - Exercise 50,000 155,000 47.62 2.31 115,500 358,050
2014-04-09 2014-01-23 4 GALE Galena Biopharma, Inc.
Common Stock
M - Exercise 100,000 105,000 2,000.00 1.18 118,000 123,900
2014-01-22 2014-01-22 4 GALE Galena Biopharma, Inc.
Stock Option (right to buy)
M - Exercise -50,000 0 -100.00
2014-01-22 2014-01-22 4 GALE Galena Biopharma, Inc.
Stock Option (right to buy)
M - Exercise -200,000 0 -100.00
2014-01-22 2014-01-22 4 GALE Galena Biopharma, Inc.
Common Stock
S - Sale -250,000 5,000 -98.04 6.13 -1,532,500 30,650
2014-01-22 2014-01-22 4 GALE Galena Biopharma, Inc.
Common Stock
M - Exercise 50,000 255,000 24.39 0.72 36,000 183,600
2014-01-22 2014-01-22 4 GALE Galena Biopharma, Inc.
Common Stock
M - Exercise 200,000 205,000 4,000.00 1.18 236,000 241,900
2014-01-22 2014-01-17 4 GALE Galena Biopharma, Inc.
Stock Option (right to buy)
M - Exercise -200,000 0 -100.00
2014-01-22 2014-01-17 4 GALE Galena Biopharma, Inc.
Common Stock
S - Sale -200,000 5,000 -97.56 7.00 -1,400,000 35,000
2014-01-22 2014-01-17 4 GALE Galena Biopharma, Inc.
Common Stock
M - Exercise 200,000 205,000 4,000.00 0.85 170,000 174,250
2013-12-11 2013-12-10 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 925,000 925,000
2013-11-27 2013-11-26 4 gale Galena Biopharma, Inc.
Stock Option (right to buy)
A - Award 200,000 200,000
2013-03-12 2013-03-08 4 CYTR CYTRX CORP
Stock Option (right to buy)
A - Award 74,176 74,176
2013-01-31 2013-01-29 4 GALE Galena Biopharma, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
2012-12-11 2012-12-10 4 4wa@gwgz CYTRX CORP
Stock Option (right to buy)
A - Award 500,000 500,000
2012-02-24 2012-02-23 4 CYTR CYTRX CORP
Common Stock
P - Purchase 105,517 4,179,776 2.59 0.33 34,451 1,364,697
2012-02-24 2012-02-22 4 CYTR CYTRX CORP
Common Stock
P - Purchase 53,159 4,074,259 1.32 0.31 16,442 1,260,168
2012-01-17 2012-01-12 4 GALE Galena Biopharma, Inc.
Stock Option (right to buy)
A - Award 50,000 50,000
2011-03-29 2011-03-25 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 200,000 200,000
2011-03-29 2011-03-25 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 100,000 100,000
2011-01-14 2011-01-13 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 50,000 50,000
2010-03-04 2010-03-02 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 50,000 50,000
2010-01-19 2010-01-14 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 50,000 50,000
2009-10-20 2009-10-16 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
A - Award 5,000 5,000
2009-08-20 2009-08-19 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -8,990 0 -100.00 3.13 -28,157
2009-07-06 2009-07-02 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,723 8,988 -16.09 4.19 -7,214 37,629
2009-07-06 2009-07-01 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,170 10,711 -9.85 4.53 -5,302 48,541
2009-07-01 2009-06-30 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -2,900 11,881 -19.62 4.45 -12,896 52,834
2009-07-01 2009-06-29 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,800 14,781 -10.86 4.65 -8,378 68,800
2009-06-29 2009-06-26 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -4,600 16,581 -21.72 4.55 -20,923 75,419
2009-06-29 2009-06-25 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,500 21,181 -6.61 4.64 -6,954 98,189
2009-06-25 2009-06-24 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -600 22,681 -2.58 4.69 -2,814 106,374
2009-06-25 2009-06-23 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -500 23,281 -2.10 4.59 -2,295 106,860
2009-06-23 2009-06-22 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,200 23,781 -4.80 4.65 -5,580 110,582
2009-06-23 2009-06-19 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,700 24,981 -6.37 4.74 -8,058 118,410
2009-06-19 2009-06-18 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,400 26,681 -4.99 4.60 -6,440 122,733
2009-06-19 2009-06-17 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,201 28,081 -4.10 4.76 -5,717 133,666
2009-06-17 2009-06-16 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -400 29,282 -1.35 4.78 -1,912 139,968
2009-06-17 2009-06-15 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,200 29,682 -3.89 4.72 -5,660 140,007
2009-06-15 2009-06-12 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -2,500 30,882 -7.49 4.96 -12,406 153,252
2009-06-15 2009-06-11 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,100 33,382 -3.19 5.13 -5,647 171,370
2009-06-11 2009-06-10 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,500 34,482 -4.17 5.02 -7,529 173,076
2009-06-11 2009-06-09 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -3,700 35,982 -9.32 4.96 -18,355 178,500
2009-06-09 2009-06-08 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -4,000 39,682 -9.16 5.04 -20,144 199,843
2009-06-09 2009-06-05 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -800 43,682 -1.80 4.92 -3,935 214,850
2009-06-05 2009-06-04 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -2,600 44,482 -5.52 4.94 -12,848 219,817
2009-06-05 2009-06-03 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -2,400 47,082 -4.85 5.11 -12,269 240,688
2009-06-03 2009-06-02 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -6,084 49,482 -10.95 5.19 -31,560 256,683
2009-06-03 2009-06-01 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -7,000 55,566 -11.19 5.04 -35,308 280,275
2009-06-01 2009-05-29 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -2,300 62,566 -3.55 5.56 -12,790 347,911
2009-06-01 2009-05-28 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,700 64,866 -2.55 5.92 -10,057 383,747
2009-05-28 2009-05-26 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -4,800 66,566 -6.73 6.00 -28,803 399,443
2009-05-13 2009-05-11 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -700 71,366 -0.97 4.93 -3,450 351,734
2009-05-11 2009-05-08 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -1,743 72,066 -2.36 4.82 -8,402 347,401
2009-05-11 2009-05-07 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -3,513 73,809 -4.54 4.59 -16,126 338,813
2009-05-07 2009-05-06 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -4,051 77,322 -4.98 4.42 -17,893 341,524
2009-05-07 2009-05-05 4 RXII RXI PHARMACEUTICALS CORP
Common
S - Sale X -5,500 81,373 -6.33 4.18 -23,016 340,522
2009-05-05 2009-05-04 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,300 86,873 -2.58 4.86 -11,178 422,203
2009-05-05 2009-05-01 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,800 89,173 -3.04 4.74 -13,279 422,903
2009-05-01 2009-04-30 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -5,500 91,973 -5.64 4.90 -26,968 450,971
2009-05-01 2009-04-29 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,700 97,473 -1.71 4.54 -7,718 442,527
2009-04-29 2009-04-28 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,200 99,173 -1.20 4.66 -5,587 461,730
2009-04-29 2009-04-27 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,700 100,373 -1.67 4.75 -8,072 476,591
2009-04-27 2009-04-24 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,000 102,073 -1.92 4.87 -9,733 496,718
2009-04-27 2009-04-23 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,800 104,073 -2.62 4.61 -12,919 480,203
2009-04-23 2009-04-22 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,000 106,873 -0.93 4.82 -4,816 514,700
2009-04-23 2009-04-21 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,900 107,873 -1.73 4.77 -9,070 514,953
2009-04-21 2009-04-20 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -300 109,773 -0.27 4.84 -1,452 531,301
2009-04-21 2009-04-17 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -3,100 110,073 -2.74 4.72 -14,646 520,040
2009-04-17 2009-04-16 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,900 113,173 -2.50 4.79 -13,883 541,793
2009-04-17 2009-04-15 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,400 116,073 -2.03 4.80 -11,528 557,557
2009-04-15 2009-04-14 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -6,300 118,473 -5.05 4.96 -31,258 587,816
2009-04-15 2009-04-13 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,700 124,773 -1.34 4.90 -8,329 611,313
2009-04-13 2009-04-09 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,200 126,473 -0.94 4.92 -5,898 621,615
2009-04-13 2009-04-08 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,400 127,673 -1.85 4.80 -11,519 612,779
2009-04-08 2009-04-07 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -800 130,073 -0.61 4.51 -3,605 586,174
2009-04-08 2009-04-06 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,409 130,873 -1.81 4.69 -11,298 613,768
2009-04-06 2009-04-03 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,400 133,282 -1.04 4.89 -6,849 652,069
2009-04-06 2009-04-02 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -3,100 134,682 -2.25 4.72 -14,641 636,090
2009-04-02 2009-04-01 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,610 137,782 -1.86 4.80 -12,538 661,877
2009-04-02 2009-03-31 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -6,033 140,392 -4.12 5.40 -32,594 758,496
2009-03-31 2009-03-13 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -900 146,425 -0.61 3.33 -2,996 487,434
2009-03-31 2009-03-30 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,100 147,325 -0.74 5.00 -5,496 736,080
2009-03-31 2009-03-27 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -600 148,425 -0.40 5.16 -3,094 765,383
2009-03-31 2009-03-27 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -4,209 149,025 -2.75 4.64 -19,520 691,133
2009-03-27 2009-03-26 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale -1,700 153,234 -1.10 3.99 -6,789 611,955
2009-03-27 2009-03-25 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,500 154,934 -0.96 3.85 -5,769 595,876
2009-03-25 2009-03-24 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -800 156,434 -0.51 3.66 -2,928 572,548
2009-03-25 2009-03-23 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -5,447 157,234 -3.35 3.84 -20,915 603,731
2009-03-23 2009-03-20 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,600 162,681 -0.97 3.60 -5,766 586,302
2009-03-23 2009-03-19 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,000 164,281 -1.20 3.45 -6,900 566,769
2009-03-19 2009-03-18 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -3,400 166,281 -2.00 3.83 -13,039 637,671
2009-03-19 2009-03-17 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,600 169,681 -1.51 3.51 -9,136 596,242
2009-03-16 2009-03-16 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,401 172,281 -1.37 3.05 -7,325 525,629
2009-03-16 2009-03-12 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,300 174,684 -0.74 3.34 -4,341 583,305
2009-03-12 2009-03-11 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,700 175,984 -1.51 3.44 -9,276 604,611
2009-03-12 2009-03-10 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -7,400 178,684 -3.98 3.17 -23,423 565,588
2009-03-10 2009-03-09 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -4,500 186,084 -2.36 2.97 -13,364 552,614
2009-03-10 2009-03-06 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,300 190,584 -0.68 3.32 -4,310 631,919
2009-03-09 2009-03-04 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,500 193,984 -0.77 3.56 -5,339 690,428
2009-03-09 2009-03-03 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,900 195,484 -1.46 3.64 -10,550 711,171
2009-03-09 2009-03-02 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -4,700 198,384 -2.31 3.76 -17,665 745,646
2009-03-09 2009-02-27 4 RXII RXI PHARMACEUTICALS CORP
Commpn Stock
S - Sale X -1,300 203,084 -0.64 4.05 -5,262 822,003
2009-03-09 2009-02-26 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -400 204,384 -0.20 4.25 -1,699 868,121
2009-03-09 2009-02-25 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -1,800 204,784 -0.87 4.25 -7,644 869,656
2009-03-09 2009-02-24 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -3,000 206,584 -1.43 4.40 -13,212 909,775
2009-03-09 2009-03-05 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
S - Sale X -2,100 191,884 -1.08 3.36 -7,057 644,865
2009-01-20 2009-01-15 4 RXII RXI PHARMACEUTICALS CORP
Stock Option
A - Award 50,000 150,000 50.00
2008-04-22 2008-04-18 4 RXII RXI PHARMACEUTICALS CORP
Non-Qualified Stock Option
A - Award 25,000 25,000
2008-03-13 2008-03-11 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
J - Other 200,594 209,584 2,231.30
2008-03-13 2008-03-11 4 RXII RXI PHARMACEUTICALS CORP
Common Stock
J - Other 8,990 8,990
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)